Adicet Bio ( (ACET) ) has provided an update.
Adicet Bio has received FDA clearance to expand its investigational new drug application, allowing the evaluation of ADI-001 in idiopathic inflammatory myopathy and stiff person syndrome as part of an ongoing Phase 1 trial. This development marks a significant step in Adicet’s efforts to tackle six autoimmune diseases using its gamma delta T cell therapies. Patient enrollment for these conditions is slated to begin in early 2025, with initial clinical data expected in the first half of the year.
For an in-depth examination of ACET stock, go to TipRanks’ Stock Analysis page.
